/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Business Of Biotech
  2. Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig
Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig

Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig

Business Of Biotech · Sep 7, 2026

Sarcomatrix CEO David Craig shares his playbook for funding a virtual biotech without institutional capital, using creative, lean strategies.

Biotech Founders Can Secure Angel Checks by Pitching at Non-Industry Events

Sarcomatrix's CEO secured six-figure checks by entering pitch contests at unrelated venues like Freedom Fest, a libertarian conference. This face-to-face interaction with high-net-worth individuals in unexpected settings proved more effective for early funding than cold outreach to traditional VCs.

Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig thumbnail

Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig

Business Of Biotech·2 months ago

Crowdfunding for Rare Diseases Fails When Patient Families Lack Disposable Income

Sarcomatrix's crowdfunding campaign raised only $52k while costing $40k in marketing. The CEO learned that for diseases like muscular dystrophy, the high cost of patient care leaves friends and family with little extra money to invest, a critical and costly miscalculation for this fundraising model.

Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig thumbnail

Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig

Business Of Biotech·2 months ago

Use Early Biotech Funding to Create Salt Variants and Extend Patent Life

Sarcomatrix used its first non-institutional funds for a CMC campaign to find new salt variants. This addressed a key investor concern about its IP, which was only method patents. The new polymorph and salt patents extended the drug's potential runway to 2047, making the company significantly more valuable and fundable.

Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig thumbnail

Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig

Business Of Biotech·2 months ago

Virtual Biotechs Must Keep CEO, Quality Systems, and Regulatory Strategy In-House

While operating a lean virtual model, Sarcomatrix's CEO advises against outsourcing three core functions. The CEO provides essential leadership, the company is ultimately responsible for quality systems regardless of its CROs, and owning the regulatory interface directly builds crucial credibility with agencies.

Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig thumbnail

Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig

Business Of Biotech·2 months ago

A Virtual Biotech Still Needs an In-House Technical Officer to Manage CDMOs

David Craig advises against fully entrusting manufacturing to a CDMO. He keeps a Chief Technical Officer in-house to manage the project plan's minutiae. This internal oversight prevents missed timelines and manages rate-limiting steps, which often derail virtual programs relying solely on external partners for execution.

Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig thumbnail

Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig

Business Of Biotech·2 months ago

A Concentrated Physician Base Makes Rare Diseases Commercially Viable for Startups

Sarcomatrix's CEO compares the muscular dystrophy market (90 clinics, 450 physicians) to the early, concentrated markets for Amgen (dialysis centers) and Gilead (AIDS clinics). This structure allows a startup to become a fully integrated company with a small, focused sales team, a key factor in its commercial viability.

Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig thumbnail

Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig

Business Of Biotech·2 months ago

Founders Should Design Pre-Seed, Seed, and Series A Rounds Simultaneously

When pursuing non-traditional financing, founders should map out all early funding rounds at once. This ensures each capital injection incrementally adds value and is structured to avoid roadblocks for the next, larger round. It prevents messy cap tables or terms from non-standard vehicles like crowdfunding that deter future institutional investors.

Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig thumbnail

Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig

Business Of Biotech·2 months ago

Amgen's 'Fermentation Seminar' Provides a Model for Virtual Team Conflict Resolution

At early Amgen, a Friday beer session was a dedicated time to clear the air between colleagues who had conflicts during the week. David Craig applies this principle of scheduled "repair" to virtual companies, advocating for annual face-to-face meetings to ensure personal conflicts don't fester in a remote environment.

Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig thumbnail

Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig

Business Of Biotech·2 months ago